OFFICAL PROJECT SITE
Novel Target for Treatment of Chronic Inflammatory Diseases — Notid
Lipum makes a share issue for faster progress
Being a European Commission Horizon 2020 beneficiary has a distinct positive impact on our development. The 2.2 M€ grant enables us to proceed faster towards a new drug against chronic inflammatory diseases. To further increase the momentum we are now raising additional funding by a share issue. Interested investors get [...]
Lipum – towards production of its lead candidate
A range of CMO partners have been evaluated for cell line development and production of Lipum’s antibody. Next weeks our CEO and CMC Project Manager will travel to both Europe and the US visiting contract manufacturers before selecting this critical collaboration partner. To be continued ...
“Investors are interested” – interview with CEO Einar Pontén
An article from Biostock In the northern of Sweden, Umeå, the privately owned company Lipum wants to draw the game plan for the treatment of chronic inflammatory diseases. The main assets are a new drug candidate and promising preclinical result for a unique target molecule. BioStock has met CEO Einar Pontén [...]
Lipum receives 2.2 M€ grant from Horizon 2020
Press release Aug 29, 2018 Lipum's unique approach for treatment of chronic inflammatory diseases receives 2.2 M€ support from EU Horizon 2020, the EU framework program for research and development, will grant 2.2 million euros to Lipum’s ongoing development of a biological pharmaceutical for treatment of chronic inflammatory diseases. Lipum [...]
Dr Einar Pontén the new CEO at Lipum AB
Press release Dec 29, 2016 The Board of Directors of Lipum AB in Umeå has appointed Dr Einar Pontén new CEO. "We are very pleased to recruit an experienced force when Lipum face a very exciting development," said Chairman Ulf Björklund. Link to Press release in Swedish»
Program:
European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741
Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases
Project budget:
3.2 M€
Funding from the EU:
2.2 M€
Start:
2018-11-01
End:
2020-07-31